Key points are not available for this paper at this time.
mutations may be considered for targeted therapies. Unfortunately, MM prognosis remains unfavorable, with a less than 50% survival rate at 2 years.
Building similarity graph...
Analyzing shared references across papers
Loading...
Laia Clavero-Rovira
Vall d'Hebron Hospital Universitari
Álvaro Gómez‐Tomás
Universitat Autònoma de Barcelona
Patricia Bassas-Freixas
Vall d'Hebron Hospital Universitari
Cancers
Universitat Autònoma de Barcelona
Vall d'Hebron Hospital Universitari
Building similarity graph...
Analyzing shared references across papers
Loading...
Clavero-Rovira et al. (Wed,) studied this question.
synapsesocial.com/papers/6a036697f32c10a08381eac3 — DOI: https://doi.org/10.3390/cancers16010227